FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jann Storsaeter

Research Profile

Chemicals & Drugs

Disorders

Whooping Cough

Living Beings

Geographic Areas

Sweden

Procedures

Concepts & Ideas

Immunization Schedule

Co-author Network

Publications

TOP 3
James D Cherry; Ulrich Heininger; David M Richards; Jann Storsaeter; Lennart Gustafsson; Margaretha Ljungman; Hans O Hallander
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
Hans O Hallander; Margaretha Ljungman; Jann Storsaeter; Lennart Gustafsson
Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
Lennart Nilsson; Rose-Marie Carlsson; Hans Olof Hallander; Margaretha Ljungman; Mårten Hallberg; Jann Storsaeter
[Good immune response of diphtheria-tetanus-pertussis vaccination in the 4th grade. Local reaction very common--and expected].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jann Storsaeter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: James D Cherry; Ulrich Heininger; David M Richards; Jann Storsaeter; Lennart Gustafsson; Margaretha Ljungman; Hans O Hallander
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
Clinical and vaccine immunology : CVI 2010;17(5):741-7.
2009: Hans O Hallander; Margaretha Ljungman; Jann Storsaeter; Lennart Gustafsson
Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(11):797-807.
2009: Lennart Nilsson; Rose-Marie Carlsson; Hans Olof Hallander; Margaretha Ljungman; Mårten Hallberg; Jann Storsaeter
[Good immune response of diphtheria-tetanus-pertussis vaccination in the 4th grade. Local reaction very common--and expected].
Läkartidningen 2009;106(38):2357-61.
2009: Hans O Hallander; Margaretha Ljungman; Maja Jahnmatz; Jann Storsaeter; Lennart Nilsson; Lennart Gustafsson
Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(9):660-71.
2009: Terhi M Kilpi; Sven-Arne Silfverdal; Lennart Nilsson; Ritva Syrjänen; Cesare Belloni; Maria Desole; Chiara Triban; Jann Storsaeter; Maaria Soila; Jeanne-Marie Jacquet
Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age.
Human vaccines 2009;5(1):18-25.
2006: Anita Svahn; Johan Berggren; Anna Parke; Jann Storsaeter; Rigmor Thorstensson; Annika Linde
Changes in seroprevalence to four herpesviruses over 30 years in Swedish children aged 9-12 years.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2006;37(2):118-23.
2006: Lennart Gustafsson; Luc Hessel; Jann Storsaeter; Patrick Olin
Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
Pediatrics 2006;118(3):978-84.
2006: Jann Storsaeter; Joanne Wolter
Is there a need for a new generation of vaccines against pertussis?
Expert opinion on emerging drugs 2006;11(2):195-205.
2005: Hans O Hallander; Lennart Gustafsson; Margaretha Ljungman; Jann Storsaeter
Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.
Vaccine 2005;23(46-47):5359-64.
2005: Lennart Nilsson; Giacomo Faldella; Jeanne-Marie Jacquet; Jann Storsaeter; Sven-Arne Silfverdal; Leif Ekholm
A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age.
Scandinavian journal of infectious diseases 2005;37(3):221-9.
2003: Jann Storsaeter; Hans O Hallander; Lennart Gustafsson; Patrick Olin
Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis.
Vaccine 2003;21(25-26):3542-9.
2003: Jann Storsaeter
[Alone and isolated].
Läkartidningen 2003;100(22):2002.
2003: Patrick Olin; Lennart Gustafsson; Luis Barreto; Luc Hessel; T Christopher Mast; Annelies Van Rie; Hugues Bogaerts; Jann Storsaeter
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine.
Vaccine 2003;21(17-18):2015-21.
2003: Per Arne Parment; Anita Svahn; Ulla Rudén; Görel Bråkenhielm; Jann Storsaeter; Lena Akesson; Annika Linde
Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Scandinavian journal of infectious diseases 2003;35(10):736-42.
2002: Hans O Hallander; Margarita Paniagua; Felix Espinoza; P Askelöf; E Corrales; M Ringman; Jann Storsaeter
Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.
Vaccine 2002;21(1-2):138-45.
2001: Patrick Olin; Hans O Hallander; Lennart Gustafsson; E Reizenstein; Jann Storsaeter
How to make sense of pertussis immunogenicity data.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33 Suppl 4():S288-91.
2000: M Tiru; Hans O Hallander; Lennart Gustafsson; Jann Storsaeter; Patrick Olin
Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster.
Vaccine 2000;18(21):2295-306.
1998: Jann Storsaeter; Hans O Hallander; Lennart Gustafsson; Patrick Olin
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Vaccine 1998;16(20):1907-16.
1998: O Wärngård; L Nilsson; C Fåhraeus; Lennart Gustafsson; Hans O Hallander; Patrick Olin; Jann Storsaeter
Catch-up primary vaccination with acellular pertussis vaccines in 3-4-year-old children--reactogenicity and serological response.
Vaccine 1998;16(5):480-4.
1997: Jann Storsaeter; Lennart Gustafsson
Absolute efficacy of acellular pertussis vaccines in household settings.
Developments in biological standardization 1997;89():153-9.
1997: H Heijbel; Marta Luisa Ciofi degli Atti; E Harzer; Johannes G Liese; M P Preziosi; F Rasmussen; Heinz-J. (Joe) Schmitt; Jann Storsaeter; J Taranger; M Uberall; Alberto Tozzi
Hypotonic hyporesponsive episodes in eight pertussis vaccine studies.
Developments in biological standardization 1997;89():101-3.
1996: L Nilsson; N I Kjellman; Jann Storsaeter; Lennart Gustafsson; Patrick Olin
Lack of association between pertussis vaccination and symptoms of asthma and allergy.
JAMA : the journal of the American Medical Association 1996;275(10):760.
1996: Lennart Gustafsson; Hans O Hallander; Patrick Olin; E Reizenstein; Jann Storsaeter
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
The New England journal of medicine 1996;334(6):349-55.
1992: Jann Storsaeter; William C Blackwelder; Hans O Hallander
Pertussis antibodies, protection, and vaccine efficacy after household exposure.
American journal of diseases of children (1960) 1992;146(2):167-72.
1992: Jann Storsaeter; Patrick Olin
Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance.
Vaccine 1992;10(3):142-4.
1991: William C Blackwelder; Jann Storsaeter; Patrick Olin; Hans O Hallander
Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions.
American journal of diseases of children (1960) 1991;145(11):1285-9.
1991: Hans O Hallander; Jann Storsaeter; R Möllby
Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial.
The Journal of infectious diseases 1991;163(5):1046-54.
1990: Jann Storsaeter; Hans O Hallander; C P Farrington; Patrick Olin; R Möllby; Elizabeth Miller
Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.
Vaccine 1990;8(5):457-61.
1989: Patrick Olin; Jann Storsaeter; V Romanus
The efficacy of acellular pertussis vaccine.
JAMA : the journal of the American Medical Association 1989;261(4):560.
1988: Jann Storsaeter; Patrick Olin; B Renemar; Teresa Lagergård; R Norberg; V Romanus; M Tiru
Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.
The Pediatric infectious disease journal 1988;7(9):637-45.
1988: L O Kallings; Patrick Olin; Jann Storsaeter
[Protective effect of 2 acellular pertussis vaccines in a double-blind placebo controlled clinical trial].
Läkartidningen 1988;85(22):1994-6.
1988: Patrick Olin; V Romanus; Jann Storsaeter
Update on acellular pertussis vaccine efficacy through September 11, 1988.
The Tokai journal of experimental and clinical medicine 1988;13 Suppl():55-7.
1988: Patrick Olin; V Romanus; Jann Storsaeter
Invasive bacterial infections during an efficacy trial of acellular pertussis vaccines--implications for future surveillance in pertussis vaccine programmes.
The Tokai journal of experimental and clinical medicine 1988;13 Suppl():143-4.